We resolve conflicting reports on DHCR7's dual roles in tumor progression (pro‐ vs. anti‐tumor effects) and immune regulation, elucidating its impact on immune checkpoint modulation and tumor microenvironment (TME) remodeling. The gene discussed is DHCR7; the disease is neoplasm.